Search
Andy Minn, MD, PhD, will return to Memorial Sloan Kettering Cancer Center (MSK) as the inaugural Chair of MSK’s new Immuno-Oncology Program in August.
Several MSK physicians and researchers presenting during the plenary sessions.
A surprising discovery linking the hormone insulin to skin pigmentation offers fresh insights into how animal bodies take shape.
Researchers have created tiny structures called organoids from patients’ prostate tumors. These organoids will allow the study of tumors in greater detail and enable correlation of genetic mutations with drug response.
Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and appointments.
Along with founding partner Equinox, Cycle for Survival begins its signature team stationary-cycling events this week in New York City. 100% of funds raised go directly to rare cancer research at Memorial Sloan Kettering Cancer Center (MSK).
If you've been treated for soft tissue sarcoma, a recurrence may be a big concern for you. Here's what MSK's sarcoma experts think you should know about the disease coming back.
Cytoreductive surgery for advanced ovarian cancer is safe in older women, even those who present with frailty.
Memorial Sloan Kettering Cancer Center (MSK) is now recognized as the first dedicated cancer center in the United States to be designated as a qualified provider-led entity (QPLE) under Medicare’s program for appropriate use criteria (AUC). This designation allows MSK to establish best practice standards for the use of CT scans, MRI, and nuclear medicine imaging from initial screening and diagnosis through all stages of cancer care, including survivorship.
Joan Massagué, Chair of the Cancer Biology and Genetics Program in the Sloan Kettering Institute, has been named the recipient of two prestigious awards.